TELESTA THERAPEUTICS INC T.TST

Help my Math

[ten10four4]

Broad stroke observations on the J P Morgan BioTech conference....well over 250 companies making a presence, most are at pre-clinical stage development, many at phase two. I'm not a mathematical wiz but if companies (example) are trading at $13.00 (year high/low 4/18).......with average trading at 175k......and have yet to hit a home run with an established immunotherapy.........why would we not expect that Telesta should be at $1+ today with potential to $5+++?

[1wascallywabbit]

How many shares OS compared to us? SH is showing us at 167mil I think. But FD including options and warrants we are getting cost to 200+mil. Maybe some of the others have 20mil giving them a comparable price of $2.50 When we get above $2 things will feel a lot better. ;-)

[beechguy]

Hey 10-4. Here is what Seeking Alpha thinks about our valuation. Bioniche (Telesta's) $25 million market cap is exceptionally low for a Phase III biotech company. How low? Here's an overview of peer Phase III small cap biotechs targeting specific cancer types with respectively their market valuations: Oncothyreon (NASDAQ:ONTY): $150 million valuation Endocyte (NASDAQ:ECYT): $280 million

[terr2]

It would seem we are the Bre-X of the biotech world. It's been a snow job from the very beginning. No credibility = No share value. jmo terr2

[IWillRetireSoon]

You are definately wrong.    Bre-X was a con where the results of drilling for gold were falsified.   Share price escalated to huge amounts based on fraudulent claims.  Investors invested tons of money due to the faked results.   They lost it all.   Person responsible killed himself by jumping out of helicopter when fraud was